IP Library Granted Patent US 11,623,943
Granted Patent B2
US 11,623,943 · App. 17/196,167 · Granted Apr 11, 2023

Method for producing lacosamide and intermediate thereof

Inventor: Masaki Nagahama (Fukuoka, JP)
Assignee: API CORPORATION
C07K5/0606A61K31/165C07B57/00C07C231/02C07C231/12C07C231/20C07C233/47C07C237/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,623,943
App. No.
17/196,167
Granted
Apr 11, 2023
Kind
B2
Abstract

The present invention provides a method of industrially and safely producing lacosamide high in diastereomeric excess at a high yield and a low cost. Adopting a particular isomerization-crystallization condition makes it possible to a method of industrially and safely producing lacosamide high in diastereomeric excess at a high yield and a low cost. Additionally, an intermediate efficacious for producing lacosamide is provided.

Claims (32)

1. A crystal of a salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-acetylamino acid, wherein

the N-acetylamino acid is N-acetyl-D-Leucine; and

the salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-acetylamino acid

has a powder X-ray diffraction measuring pattern using a CuKα ray exhibiting peaks at diffraction angles (2θ±0.2°)=6.3°, 15.8°, 18.1°, 23.4° and 25.2°.

2. A crystal of a salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-acetylamino acid, wherein

the N-acetylamino acid is N-acetyl-D-Valine; and

the salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-acetylamino acid

has a powder X-ray diffraction measuring pattern using a CuKα ray exhibiting peaks at diffraction angles (2θ±0.2°)=7°, 14.8°, 18.7°, 21.9° and 24.6°.

3. A crystal of a salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-formylamino acid, wherein

the N-formylamino acid is N-formyl-L-Leucine; and

the salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-formylamino acid

has a powder X-ray diffraction measuring pattern using a CuKα ray exhibiting peaks at diffraction angles (2θ±0.2°)=4.9°, 9.4°, 12.4°, 18.7°, 24.9° and 26.9°.

4. A crystal of a salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-formylamino acid, wherein

the N-formylamino acid is N-formyl-L-Alanine; and

the salt of R-configuration of

N-benzyl-2-amino-3-methoxypropionamide and

N-formylamino acid

has a powder X-ray diffraction measuring pattern using a CuKα ray exhibiting peaks at diffraction angles (2θ±0.2°)=9.9°, 12°, 17.8°, 19.8°, 22.4°, 24° and 25.3°.

Assignments (3)
CHANGE OF ADDRESS Recorded Aug 21, 2025
From: API CORPORATION
To: API CORPORATION
Reel/Frame 072498/0511 →
MERGER Recorded Aug 21, 2025
From: API CORPORATION
To: UBE CORPORATION
Reel/Frame 072554/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: NAGAHAMA, MASAKI
To: API CORPORATION
Reel/Frame 055536/0874 →
Priority Claims (1)
JP 2015-222754 · Nov 13, 2015 · national
Continuity (2)
Division 15775581
Related Publication 20210188904A1 · Jun 24, 2021